Atherosclerosis in AIDS: Potential pathogenetic roles of antiretroviral therapy and HIV

Journal of Molecular and Cellular Cardiology

Volumn 32, Issue 12, 2000, Pages 2115-2129

  Lewis, William ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN; CYTOKINE; FIALURIDINE; LAMIVUDINE; NITRIC OXIDE SYNTHASE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; REGULATOR PROTEIN; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ATHEROSCLEROSIS; BODY COMPOSITION; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS; ENDOTHELIUM LESION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LIPODYSTROPHY; MITOCHONDRION; OXIDATIVE STRESS; PATHOGENESIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW;

EID: 0034513210     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.2000.1271     Document Type: Review

References (174)

1. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency
2. Prevalence of HIV infection in the United States, 1984 to 1992
3. Scope of the ADS epidemic in the United States
4. The AIDS epidemic - Considerations for the 21st century
5. UN acknowledges HIV/AIDS as a threat to world peace
6. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)
7. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
8. The molecular biology of human immunodeficiency virus type 1 infection
9. HIV as the cause of AIDS
10. Site-directed mutagenesis of two trans-regulatory genes (tat-III, trs) of HIV-1
11. Molecular biology of the human immunodeficiency virus type 1
12. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus
13. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV
14. Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule
15. Biochemical analysis of human T lymphocyte differentiation antigens T4 and T5
16. Immunopathogenesis of HIV infection
17. AIDS-related Kaposi's sarcoma: A review of its pathogenesis and treatment
18. HIV and malignancy
19. The brain in AIDS: Central nervous system HIV-1 infection and AIDS dementia complex
20. HIV-1, macrophages, glial cells, and cytokines in AIDS nervous system disease
21. Acquired immunodeficiency syndrome and non-Hodgkin's lymphomas
22. HIV-associated nephropathy. A unique combined glomerular, tubular, and interstitial lesion
23. The nephropathology in human immunodeficiency virus (HIV-1) infection
24. Autopsy findings in the acquired immune deficiency syndrome
25. Cardiac lesions in acquired immune deficiency syndrome (AIDS)
26. Cryptococcal myocarditis in acquired immune deficiency syndrome
27. Frequency of myocarditis, left ventricular dysfunction and ventricular tachycardia in the acquired immune deficiency syndrome
28. AIDS: Cardiac findings from 115 autopsies
29. Infection of the heart by the human immunodeficiency virus
30. Zidovudine causes early increases in mitochondrial ribonucleic acid abundance and induces ultrastructural changes in cultured mouse muscle cells
31. AIDS and the heart: Review and consideration of pathogenetic mechanisms
32. Pathologic changes in the hearts of patients with AIDS
33. Acquired immune deficiency syndrome: Postmortem findings
34. Cardiac complications in acquired immunodeficiency syndrome (AIDS): A review
35. Necropsy findings in acquired immunodeficiency syndrome: A comparison of premortem diagnoses with postmortem findings
36. Cardiac involvement in the acquired immune deficiency syndrome
37. Autopsy pathology in the acquired immune deficiency syndrome
38. Cardiomyopathy in AIDS: A pathophysiological perspective
39. Emerging patterns of heart disease in human immunodeficiency virus infection
40. Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome
41. Pericardial effusion in AIDS. Incidence and survival
42. Identification of human immunodeficiency virus-1 RNA and DNA in the heart of a child with cardiovascular abnormalities and congenital acquired immune deficiency syndrome
43. Dilated cardiomyopathy associated with simian AIDS in nonhuman primates
44. Dyslipidemia and other risk factors for coronary artery disease
45. Atherosclerosis - An inflammatory disease
46. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitorassociated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
47. Studies of body composition and fat distribution in HIV-infected and control subjects
48. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
49. HIV-1: Fifteen proteins and an RNA
50. HTLV-III gag protein is processed in yeast cells by the virus pol-protease
51. An 11-kDa form of human immunodeficiency virus protease expressed in Escherichia coli is sufficient for enzymatic activity
52. Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation
53. Active human immunodeficiency virus protease is required for viral infectivity
54. HIV-protease inhibitors
55. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector
56. The HIV-1 protease as a therapeutic target for AIDS
57. Viral dynamics in human immunodeficiency virus type I infection
58. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
59. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
60. Rational design of peptide-based HIV proteinase inhibitors
61. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans
62. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease
63. L-735,524: An orally bio-available human immunodeficiency virus type 1 protease inhibitor
64. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor
65. Selective bio-transformation of the human immunodeficiency virus protease inhibitor saquinavir by human smallintestinal cytochrome P4503A4: Potential contribution to high first-pass metabolism
66. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes
67. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor
68. SC-52151, a novel inhibitor of the human immunodeficiency virus protease
69. Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein
70. In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: A comparative study with other relevant HIV protease inhibitors
71. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins
72. Effect of protein binding on the pharmacodynamics of an HIV protease inhibitor
73. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
74. Marked hypertriglyceridaemia associated with ritonavir therapy
75. Myocardial infarction in HIV-infected men receiving protease inhibitors
76. Severe premature coronary artery disease with protease inhibitors
77. Vascular complications associated with use of HIV protease inhibitors
78. Vascular complications associated with use of HIV protease inhibitors
79. Vascular complications associated with use of HIV protease inhibitors
80. Vascular complications associated with use of HIV protease inhibitors
81. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors
82. Increased Morbidity from Severe Coronary Heart Disease in HIV-patients Receiving Protease Inhibitors
83. Do Protease Inhibitors Increase the Risk for Coronary Heart Disease Among HIV Positive Patients?
84. Endothelial Dysfunction Is Associated with the Use of Human Immunodeficiency Virus-1 Protease Inhibitors
85. Noinvasive Morphological Analysis of Carotid and Femoral Arteries in Protease-Inhibitor-Treated HIV-Infected Individuals
86. Diagnosis and Determinants of Subclinical Arterial Disease in HIV-1-infected Patients on HAART
87. Hypertension (HTN) in HIV Patients with Metabolic Dysregulation
88. A Pilot Study of Carotid Intima Media Thickness (IMT) in HIV-infected Women Treated with Protease Inhibitors
89. DO Protease Inhibitors Increase the Risk for Coronary Heart Disease among HIV-Positive Patients
90. Myocardial Infarction Incidence in Clinical Trials of 4 Protease Inhibitors
91. Detection of Myocardial Ischemia in Protease Inhibitor (PI)-Treated HIV-Infected Patients with Hyperlipemia
92. Coronary artery lesions and human immunodeficiency virus infection
93. No association observed between Indinavir therapy for HIV/AIDS and myocardial infarction in 4 clinical trials with 2,825 subjects
94. High Fat Diet and Susceptibility to Obesity Increase the Effects of HIV Protease Inhibitors on Metabolism in Mice
95. Nelfinavir and Ritonavir Stimulate Triglycerides Production in Hepatic Cells
96. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
97. Mitochondrial toxicity of antiviral drugs
98. Cellular and molecular mechanisms of endothelial cell dysfunction
99. Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts
100. Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria
101. Mitochondrial toxicity - New adverse drug effects
102. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
103. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy
104. Hypoxemia is associated with mitochondrial DNA damage and gene induction. Implications for cardiac disease
105. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
106. Eukaryotic DNA polymerases
107. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine
108. Mammalian DNA polymerases alpha, beta, gamma, delta, and epsilon incorporate fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU Triphosphate
109. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts
110. Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine
111. Aortas from NL4-3 gag/pol AIDS mice have impaired endothelium-dependent relaxation
112. Differences in Anion Gap with Different Nucleoside RTI Combinations
113. Hyperlactatemia in 20 Patients Receiving NRTI Combination Regimens
114. Hyperlactatemia and Antiretroviral Therapy in the Swiss HIV Cohort Study (SHCS)
115. Four Cases of Fatal Lactic Acidosis Due to Mitochondrial Toxicity of NRTI Treatment: Analysis of Clinical Features and Risk Factors
116. Near-Fatal Metabolic Acidosis, Liver Failure in Mitochondrial (mt) DNA Depletion in an HIV-Infected Child Treated with Combination Antiretroviral Therapy (ART)
117. Differential effects of anti-retroviral nucleoside analogs on mitochondrial function in HepG2 cells
118. HIV-related vasculitis
119. Aortic endothelium in HIV-1 infection: Chronic injury, activation, and increased leukocyte adherence
120. Infection of the retina by human immunodeficiency virus type I
121. Productive in vitro infection of human umbilical vein endothelial cells and three colon carcinoma cell lines with HIV-1
122. Upregulation of human immunodeficiency virus-1 in chronically infected monocytic cell line by both contact with endothelial cells and cytokines
123. Productive HIV-1 infection of human vascular endothelial cells requires cell proliferation and is stimulated by combined treatment with interleukin-1 beta plus tumor necrosis factor-alpha
124. Biosynthesis and action of nitric oxide in mammalian cells
125. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease
126. Interactions between L-arginine and L-glutamine change endothelial NO production. An effect independent of NO synthase substrate availability
127. The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: Cultured endothelial cells recycle L-citrulline to L-arginine
128. Regulation of L-arginine transport and nitric oxide release in superfused porcine aortic endothelial cells
129. Cytokines regulate endotoxin stimulation of endothelial cell arginine transport
130. Selective induction of a cationic amino acid transporter by tumor necrosis factor-alpha in vascular endothelium
131. Activation of L-arginine transport (system y +) and nitric oxide synthase by elevated glucose and insulin in human endothelial cells
132. Nitric oxide synthases: Which, where, how, and why?
133. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels
134. Posttranscriptional regulation of endothelial nitric oxide synthase during cell growth
135. Cytokine modulation of HIV expression
136. Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta
137. Loss of endothelial pertussis toxin-sensitive G protein function in atherosclerotic porcine coronary arteries
138. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta
139. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells
140. Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton
141. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane
142. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth
143. Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle
144. Identification, sequence, and expression of caveolin-2 defines a caveolin gene family
145. Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolinrich insoluble complex in MDCK cells
146. Dissecting the interaction between nitric oxide sythase (NOS) and caveolin. Functional significance of the non caveolin binding domain in vivo
147. Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases
148. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins
149. Tumor necrosis factor and HIV P24 antigen levels in serum of HIV-infected populations
150. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome
151. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life
152. Combination antiretroviral therapy. Back to the future
153. In search of a selective antiviral chemotherapy
154. Long term virological and immunological effect of the HIV protease inhibitor Viracept in combination with zidovudine and lamivudine
155. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection
156. Prevalence of toxoplasma myocarditis in patients with the acquired immunodeficiency syndrome
157. Human immunodeficiency virus-1-tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells
158. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients
159. Angiogenic properties of human immunodeficiency virus type 1 Tat protein
160. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS
161. The biochemistry of AIDS
162. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation
163. HIV-1 trans-activator protein Tat induces proliferation and TGF beta expression in human articular chondrocytes
164. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis
165. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells
166. HIV-tat protein is a heparin-binding angiogenic growth factor
167. Prevalence and Risk Factors for Hyperglycemia, Dyslipidemia, and Coronary Disease Among HIV-Infected Patients on Initial Protease Inhibitor Therapy
168. Description of lipodystrophy in the HIV outpatient study (HOPS)
169. Diabetes and Hyperglycemia in Patients Receiving Protease Inhibitors
170. Effects of Protease Inhibitors Use on Hyperglycemia and Hyperlipidemia: A Five Year Analysis
171. High Prevalence of Impaired Glucose Tolerance Prior to Initiating Protease Inhibitor Therapy